Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
Verastem Oncology (VSTM), focusing on RAS/MAPK pathway-driven cancer treatments, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. The company's management will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 1:00 PM EST.
Investors and interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Verastem's website. The recorded session will remain available for approximately 90 days following the presentation on the company's website at www.verastem.com.
Verastem Oncology (VSTM), che si concentra sui trattamenti per il cancro guidati dalla via RAS/MAPK, ha annunciato la sua prossima partecipazione alla Guggenheim SMID Cap Biotech Conference. La direzione dell'azienda parteciperà a una conversazione informale programmata per mercoledì 5 febbraio 2025, alle 13:00 EST.
Gli investitori e le parti interessate possono accedere a un webcast live della presentazione attraverso la sezione 'Eventi e Presentazioni' del sito web di Verastem. La registrazione della sessione rimarrà disponibile per circa 90 giorni dopo la presentazione sul sito dell'azienda all'indirizzo www.verastem.com.
Verastem Oncology (VSTM), centrada en tratamientos contra el cáncer impulsados por la vía RAS/MAPK, ha anunciado su próxima participación en la Guggenheim SMID Cap Biotech Conference. La dirección de la compañía participará en una charla informal programada para miércoles 5 de febrero de 2025, a la 1:00 PM EST.
Los inversores y partes interesadas pueden acceder a un webcast en vivo de la presentación a través de la sección 'Eventos y Presentaciones' en el sitio web de Verastem. La sesión grabada estará disponible durante aproximadamente 90 días después de la presentación en el sitio web de la compañía en www.verastem.com.
Verastem Oncology (VSTM)는 RAS/MAPK 경로 기반 암 치료에 집중하며, 구겐하임 SMID Cap 바이오텍 회의에 참가할 예정이라고 발표했습니다. 회사 경영진은 2025년 2월 5일 수요일, 오후 1시 EST에 예정된 대담에 참여할 것입니다.
투자자 및 관심 있는 이는 Verastem 웹사이트의 '이벤트 및 발표' 섹션을 통해 프레젠테이션의 실시간 웹캐스트에 접근할 수 있습니다. 프레젠테이션 후 약 90일 동안 회사 웹사이트 www.verastem.com에서 기록된 세션을 이용할 수 있습니다.
Verastem Oncology (VSTM), qui se concentre sur les traitements contre le cancer dirigés par la voie RAS/MAPK, a annoncé sa prochaine participation à la Guggenheim SMID Cap Biotech Conference. La direction de l'entreprise participera à une discussion informelle prévue pour mercredi 5 février 2025, à 13h00 EST.
Les investisseurs et les parties intéressées peuvent accéder à un webcast en direct de la présentation via la section 'Événements & Présentations' du site web de Verastem. La session enregistrée restera disponible pendant environ 90 jours après la présentation sur le site de l'entreprise à l'adresse www.verastem.com.
Verastem Oncology (VSTM) konzentriert sich auf Krebsbehandlungen, die durch den RAS/MAPK-Weg gesteuert werden, und hat seine bevorstehende Teilnahme an der Guggenheim SMID Cap Biotech Conference angekündigt. Das Management des Unternehmens wird an einem informellen Gespräch teilnehmen, das für Mittwoch, den 5. Februar 2025, um 13:00 Uhr EST geplant ist.
Investoren und Interessierte können über den Bereich 'Events & Präsentationen' auf der Website von Verastem auf einen Live-Webcast der Präsentation zugreifen. Die aufgezeichnete Sitzung wird etwa 90 Tage nach der Präsentation auf der Unternehmenswebsite unter www.verastem.com verfügbar sein.
- None.
- None.
A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors & Media section of the company’s website at www.verastem.com. A replay of the webcast will be archived on the website for approximately 90 days following the presentation.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250129682351/en/
For Investor and Media Inquiries:
Julissa Viana
Vice President, Corporate Communications and Investor Relations
investors@verastem.com or
media@verastem.com
Source: Verastem Oncology
FAQ
When is Verastem Oncology (VSTM) presenting at the Guggenheim SMID Cap Biotech Conference?
How long will the VSTM Guggenheim Conference webcast be available for replay?
Where can investors access the VSTM Guggenheim Conference presentation webcast?
What type of cancers does Verastem Oncology (VSTM) focus on treating?
